

# Development of a National Plasma Plan in Sweden

Lisa-Mari Mörk,  
Med dr, Programme Officer  
The National Board of Health and Welfare  
Department for Health and Medical Care  
National Donation Center

# Government assignment

- The National Board of Health and Welfare, together with the Swedish Medical Products Agency, has investigated the conditions for increased collection of plasma for the production of PDMPs. The final report on the assignment was submitted to the Ministry of Health and Social Affairs on 5 June 2025.
- On 19 June 2025, the National Board of Health and Welfare was given a new assignment to continue strengthening the supply of blood plasma for pharmaceutical production. The final report on the assignment is to be submitted by 5 June 2026 at the latest.



# Collection of plasma for PDMP production today

- The Swedish health care system is **decentralized**, which means that it is managed and run either by the regions, local authority or municipality
  - Every county council, local authority or municipality is responsible for managing and prioritizing its own healthcare resources.
- All plasma collection in Sweden is carried out by the blood services
  - 85% of the plasma is recovered plasma
  - Few facilities have plasmapheresis.

The primary goal of blood donation today is to supply healthcare with various blood components for patients, and it is the healthcare sector's demand for these blood components that determines the amount of blood collected.





# Self-sufficiency rate

The collection of plasma for pharmaceutical manufacturers has declined, while the use of immunoglobulin has increased over the past 10 years.

The current national plasma collection for manufacturing purposes covers approximately 20 % of the national use of immunoglobulins.

For human albumin, the self-sufficiency rate is estimated to be around 50 %.



# A national plasma strategy

- To achieve a significant and long-term self-sufficiency, a **national actor** with clear formal responsibility is required to ensure supply of plasma for PDMP production.
- A **national plasma strategy** that clarifies responsibilities, creates shared governance, and enables coordination between actors. Three areas are highlighted as particularly important:
  - Expansion of plasmapheresis
  - Development of a procurement and contracting model
  - Continuous national monitoring of plasma availability and self-sufficiency rates in relation to plasma-derived medicinal products.



# Actions for implementation

- Expansion of **plasmapheresis** in Sweden and strategic placement of these plasmapheresis facilities
  - Pilot study in a selected region to generate data and cost calculations for a large-scale plasmapheresis center
  - Development of targeted information materials for healthcare professionals and the general public.
- Assessment of a national **procurement and contracting model** linking plasma collection to the supply of plasma-derived medicinal products through public–industry agreements.
- Continuous **national monitoring** of plasma availability and self-sufficiency rates in relation to PDMPs
  - The Swedish Medical Products Agency (MPA) are developing an app for monitoring pharmaceutical sales data.



**Thank you!**

